Children with perinatally acquired HIV (PHIV) have special vaccination needs, as they make suboptimal immune responses. Here, we evaluated safety and immunogenicity of 2 doses of 4 -component group B meningococcal vaccine in antiretroviral therapy-treated children with PHIV and healthy controls (HCs). Assessments included the standard human serum bactericidal antibody (hSBA) assay and measurement of IgG titers against capsular group B Neisseria meningitidis antigens (fHbp, NHBA, NadA). The B cell compartment and vaccine -induced antigen -specific (fHbp + ) B cells were investigated by flow cytometry, and gene expression was investigated by multiplexed real-time PCR. A good safety and immunogenicity profile was shown in both groups; however, PHIV demonstrated a reduced immunogenicity compared with HCs. Additionally, PHIV showed a reduced frequency of fHbp + and an altered B cell subset distribution, with higher fHbp + frequency in activated memory and tissue -like memory B cells. Gene expression analyses on these cells revealed distinct mechanisms between PHIV and HC seroconverters. Overall, these data suggest that PHIV presents a diverse immune signature following vaccination. The impact of such perturbation on long-term maintenance of vaccine -induced immunity should be further evaluated in vulnerable populations, such as people with PHIV.
Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine / N. Cotugno, A. Neri, M. Sanna, V. Santilli, E.C. Manno, G.R. Pascucci, E. Morrocchi, D. Amodio, A. Ruggiero, M.L. Ciofi degl Atti, I. Barneschi, S. Grappi, I. Cocchi, V. Giacomet, D. Trabattoni, G. Olivieri, S. Bernardi, D. O'Connor, E. Montomoli, A.J. Pollard, P. Palma. - In: JCI INSIGHT. - ISSN 2379-3708. - 9:10(2024 May), pp. e177182.1-e177182.14. [10.1172/jci.insight.177182]
Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine
V. Giacomet;D. Trabattoni;
2024
Abstract
Children with perinatally acquired HIV (PHIV) have special vaccination needs, as they make suboptimal immune responses. Here, we evaluated safety and immunogenicity of 2 doses of 4 -component group B meningococcal vaccine in antiretroviral therapy-treated children with PHIV and healthy controls (HCs). Assessments included the standard human serum bactericidal antibody (hSBA) assay and measurement of IgG titers against capsular group B Neisseria meningitidis antigens (fHbp, NHBA, NadA). The B cell compartment and vaccine -induced antigen -specific (fHbp + ) B cells were investigated by flow cytometry, and gene expression was investigated by multiplexed real-time PCR. A good safety and immunogenicity profile was shown in both groups; however, PHIV demonstrated a reduced immunogenicity compared with HCs. Additionally, PHIV showed a reduced frequency of fHbp + and an altered B cell subset distribution, with higher fHbp + frequency in activated memory and tissue -like memory B cells. Gene expression analyses on these cells revealed distinct mechanisms between PHIV and HC seroconverters. Overall, these data suggest that PHIV presents a diverse immune signature following vaccination. The impact of such perturbation on long-term maintenance of vaccine -induced immunity should be further evaluated in vulnerable populations, such as people with PHIV.File | Dimensione | Formato | |
---|---|---|---|
cotugno n 2024.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.56 MB
Formato
Adobe PDF
|
1.56 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.